Vinorelbine plus cisplatin in the treatment of advanced non-small cell lung cancer previously treated with taxane-based chemotherapy.
- Author:
Wen ZHANG
1
;
Jun-ning CAO
;
Ji-liang YIN
;
Xiao-nan HONG
;
Li-gong XU
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; therapeutic use; Carcinoma, Non-Small-Cell Lung; drug therapy; mortality; Cisplatin; administration & dosage; adverse effects; Female; Humans; Lung Neoplasms; drug therapy; mortality; Male; Middle Aged; Survival Rate; Vinblastine; administration & dosage; adverse effects; analogs & derivatives
- From: Chinese Journal of Oncology 2003;25(6):587-589
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the efficacy and toxicity of vinorelbine plus cisplatin in the treatment of advanced non-small cell lung cancer (NSCLC) previously treated with taxane-based chemotherapy.
METHODSThirty patients (0 - 1 score ECOG performance status) with stage IIIB/IV NSCLC previously treated with taxane-based chemotherapy were eligible for the study. Fifteen patients received the regimen of vinorelbine plus cisplatin (NP), the others received mitomycin, vindesine plus cisplatin (MVP).
RESULTSThe overall response rates were 13.3% in NP and 0 in MVP (P > 0.05). Time to progression was longer for NP patients than that for MVP ones (6 v 3 months, P < 0.05), so was median survival (9 v 6 months, P < 0.05). The 1-year survival rate of 40.0% in the NP group was significantly higher than that of 0 in MVP (P < 0.05). Grade III-IV toxicity was observed at a similar rate in both groups (P > 0.05), though both well tolerated.
CONCLUSIONRegimen of vinorelbine plus cisplatin is appropriate for good performance status patients with advanced non-small cell lung cancer previously treated with taxane-based chemotherapy. Time to progression, median survival and 1-year survival are satisfactory in patients treated with NP, which is complicated with acceptable toxicity.
